Opportunity Information: Apply for GH BAA 2018 ADDENDUM02
The "Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance" opportunity (Funding Opportunity Number: GH BAA 2018 ADDENDUM02) is a U.S. Agency for International Development (USAID) discretionary funding announcement in the health area (CFDA 98.001). It is designed to catalyze research and development solutions that are not only technically strong, but also market-driven and built to last without permanent donor support. The core idea is to harness private sector capabilities, incentives, and speed to complement public sector mandates and reach, especially in areas where governments cannot effectively act alone.
At the center of the challenge is the link between animal health, human health, and food systems. Applicants are expected to propose innovations that simultaneously move the needle on two big global goals: expanding access to safe, affordable, high-quality animal-source foods (such as meat, eggs, dairy, and fish) and strengthening global health security by reducing the risks posed by emerging zoonoses (diseases that spill over from animals to humans), trans-boundary animal diseases (diseases that spread across borders and disrupt trade and livelihoods), and antimicrobial resistance (AMR). In practice, this means proposals should treat livestock and animal-source food value chains as both an economic engine and a potential pathway for disease emergence, then offer solutions that increase productivity and nutrition while reducing health threats.
A defining feature of this opportunity is its emphasis on public-private collaboration as the main mechanism for change. Proposed solutions should sit at the intersection of government priorities and private sector execution, showing clearly how partners will work together in a way that creates additional value. USAID is looking for approaches that either build on existing tools and systems in a meaningful way or introduce new approaches that go beyond what public institutions can realistically develop, fund, scale, or sustain on their own. That generally implies leveraging private sector assets like distribution networks, manufacturing capacity, data systems, financing, product development pipelines, or service delivery models, while aligning with public sector needs such as surveillance, standards, regulatory enforcement, and equitable access.
The announcement also signals that solutions should be designed with real-world variation in mind. Because disease risks, agricultural practices, regulatory environments, and market readiness differ significantly by region, strong concepts are expected to account for differences in policy, capacity, and local incentives. At the same time, USAID is explicitly interested in approaches that have the potential to be widely applicable and scalable, rather than one-off pilots that only work in a narrow context. In other words, adaptability to local conditions should be built in, but the underlying model should be capable of expansion across geographies.
Operationally, the opportunity is open to unrestricted eligible applicants, indicating a broad pool of potential submitters that can include private companies, consortia, nonprofit organizations, and other entities that can credibly lead or participate in market-based R&D partnerships. The award ceiling is listed at up to $40,000,000, suggesting support for large, multi-partner efforts with meaningful scale or ambition. The original closing date is June 24, 2019, and the opportunity record shows a creation date of May 15, 2019, placing it within a timeframe when global health security and One Health approaches were increasingly being tied to food systems, agricultural development, and private sector engagement.
Overall, this grant opportunity is aimed at generating sustainable innovations at the One Health nexus, where improvements in animal-source food production and safety can be pursued in tandem with better prevention and control of zoonotic threats, cross-border animal disease spread, and antimicrobial resistance. The strongest proposals under this kind of challenge are typically those that can demonstrate a viable market pathway, clear incentives for private sector participation, credible collaboration with public authorities, and a strategy for scaling solutions beyond a single project footprint while still fitting local realities.Apply for GH BAA 2018 ADDENDUM02
- The Agency for International Development in the health sector is offering a public funding opportunity titled "Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 98.001.
- This funding opportunity was created on 2019-05-15.
- Applicants must submit their applications by 2019-06-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $40,000,000.00 in funding.
- Eligible applicants include: Unrestricted.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance (GH BAA 2018 ADDENDUM02)
1) What is the name of this funding opportunity?
The opportunity is titled "Private Sector Partnership Addressing Emerging Zoonoses and Antimicrobial Resistance".
2) What is the Funding Opportunity Number?
The Funding Opportunity Number is GH BAA 2018 ADDENDUM02.
3) Which agency is offering this opportunity?
This is a discretionary funding announcement from the U.S. Agency for International Development (USAID).
4) What is the program area and assistance listing associated with this opportunity?
The opportunity is in the health area and is associated with CFDA 98.001.
5) What is the overall purpose of the opportunity?
The purpose is to catalyze research and development solutions that are technically strong, market-driven, and designed to last without permanent donor support, by harnessing private sector capabilities alongside public sector mandates and reach.
6) What kinds of solutions is USAID trying to catalyze?
USAID is seeking innovations that connect animal health, human health, and food systems, and that can be sustained through viable market pathways rather than relying on long-term donor funding.
7) What major global goals should proposed innovations address?
Applicants are expected to propose innovations that advance two goals at the same time: (1) expanding access to safe, affordable, high-quality animal-source foods (for example, meat, eggs, dairy, and fish) and (2) strengthening global health security by reducing risks from emerging zoonoses, trans-boundary animal diseases, and antimicrobial resistance (AMR).
8) What does "One Health nexus" mean in the context of this opportunity?
Within this announcement, the One Health nexus refers to the practical link between animal health, human health, and food systems, especially where livestock and animal-source food value chains can drive economic growth while also serving as potential pathways for disease emergence.
9) What specific health threats are in scope?
The announcement highlights three categories: emerging zoonoses (diseases that spill over from animals to humans), trans-boundary animal diseases (diseases that cross borders and disrupt trade and livelihoods), and antimicrobial resistance (AMR).
10) How should proposals treat livestock and animal-source food value chains?
Proposals are expected to treat livestock and animal-source food value chains both as (a) an economic engine that can improve productivity and nutrition and (b) a risk pathway for disease emergence, then present solutions that improve production and food access while reducing health threats.
11) What is the primary mechanism for change emphasized by this opportunity?
A defining feature is public-private collaboration. USAID is looking for solutions that sit at the intersection of government priorities and private sector execution and that create additional value through partnership.
12) What does USAID mean by "market-driven and built to last"?
Based on the announcement description, this means solutions should have a viable market pathway and be structured so they can be sustained and scaled without permanent donor support.
13) What role is the private sector expected to play?
The private sector is expected to bring capabilities, incentives, and speed, and to leverage assets such as distribution networks, manufacturing capacity, data systems, financing, product development pipelines, or service delivery models.
14) What role is the public sector expected to play?
Public sector priorities and functions referenced include surveillance, standards, regulatory enforcement, and equitable access. Proposals should show how private sector execution aligns with these public needs.
15) Are applicants expected to build on existing tools or propose new approaches?
Either can fit. USAID indicates interest in approaches that build on existing tools and systems in a meaningful way or introduce new approaches that go beyond what public institutions can realistically develop, fund, scale, or sustain on their own.
16) How important is scalability versus piloting?
USAID is explicitly interested in approaches with potential to be widely applicable and scalable, rather than one-off pilots that only work in a narrow context.
17) How should proposals handle differences across regions and markets?
Strong concepts are expected to account for variation in disease risks, agricultural practices, regulatory environments, policy, capacity, and local incentives, while still maintaining an underlying model that can expand across geographies.
18) Who is eligible to apply?
The opportunity is open to unrestricted eligible applicants, signaling a broad pool that can include private companies, consortia, nonprofit organizations, and other entities that can credibly lead or participate in market-based R&D partnerships.
19) What is the maximum award amount?
The award ceiling is listed as up to $40,000,000.
20) What does the listed award ceiling suggest about the kinds of projects USAID expects?
The ceiling suggests USAID may support large, multi-partner efforts with meaningful scale or ambition, consistent with the emphasis on market-based R&D and scalable solutions.
21) What is the closing date listed for this opportunity?
The original closing date is June 24, 2019.
22) When was the opportunity record created?
The opportunity record shows a creation date of May 15, 2019.
23) What types of outcomes would a strong proposal typically demonstrate (based on the announcement description)?
The description suggests stronger proposals will typically demonstrate a viable market pathway, clear incentives for private sector participation, credible collaboration with public authorities, and a scaling strategy that goes beyond a single project footprint while fitting local realities.
24) Does the opportunity prioritize solutions that governments cannot do alone?
Yes. The announcement frames the effort as complementing public sector mandates and reach, particularly where governments cannot effectively act alone, by leveraging private sector capabilities and assets.
25) What is the core "problem statement" that this opportunity is trying to address?
The core challenge is the interconnectedness of animal health, human health, and food systems, where improving animal-source food production and safety must be pursued in tandem with preventing and controlling zoonotic threats, cross-border animal disease spread, and antimicrobial resistance.
Browse more opportunities from the same category: Health
Next opportunity: Romania: Debate Clubs for High Schools in Select Counties
Previous opportunity: Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for GH BAA 2018 ADDENDUM02
Applicants also applied for:
Applicants who have applied for this opportunity (GH BAA 2018 ADDENDUM02) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) Apply for PAR 19 281 Funding Number: PAR 19 281 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed) Apply for RFA RM 19 004 Funding Number: RFA RM 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Innovations in Malaria Vaccine Development (IMV) Apply for GH BAA 2018 ADDENDUM03 Funding Number: GH BAA 2018 ADDENDUM03 Agency: Agency for International Development Category: Health Funding Amount: $35,500,000 |
| Postdoctoral Research Associate Training (PRAT) Program (Fi2) Apply for PAR 19 286 Funding Number: PAR 19 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed) Apply for RFA TR 19 020 Funding Number: RFA TR 19 020 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Enhanced Diversity Clinical Sites (U01 Clinical Trial Required) Apply for RFA HG 19 014 Funding Number: RFA HG 19 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement to Support Navigators in Federally-facilitated Exchanges Apply for CA NAV 19 001 Funding Number: CA NAV 19 001 Agency: CMS-Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) Apply for RFA HG 19 015 Funding Number: RFA HG 19 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIA Genome Center for Alzheimer's Disease (U54 Clinical Trial Not Allowed) Apply for PAR 19 288 Funding Number: PAR 19 288 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 025 Funding Number: RFA AG 20 025 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) Apply for PAR 19 289 Funding Number: PAR 19 289 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Adolescent Health and Well-Being in Urban Areas Apply for BAA NIGERIA HPNIAH 2019 Funding Number: BAA NIGERIA HPNIAH 2019 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed) Apply for RFA AI 19 042 Funding Number: RFA AI 19 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed) Apply for RFA AI 19 043 Funding Number: RFA AI 19 043 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Oscillatory Patterns of Gene Expression in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 040 Funding Number: RFA AG 20 040 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Exploratory Grant for NIA Alzheimers Disease Research Center (P20 Clinical Trial Not Allowed) Apply for RFA AG 20 023 Funding Number: RFA AG 20 023 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed) Apply for RFA HL 20 007 Funding Number: RFA HL 20 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Interpersonal Processes in Alzheimer's Disease and Related Dementias Clinical Interactions and Care Partnerships (R01 Clinical Trial Optional) Apply for RFA AG 20 006 Funding Number: RFA AG 20 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Cardiovascular Developmental Biology Data Resource Center (U01 - Clinical Trial Not Allowed) Apply for RFA HL 20 017 Funding Number: RFA HL 20 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biology of Aging in Reproductive Tissues (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 036 Funding Number: RFA AG 20 036 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "GH BAA 2018 ADDENDUM02", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.